Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16209754 | 0.98 | ADRA2C (0.96) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL2649456 | 0.93 | ADRA2C (0.86) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL6942579 | 0.89 | ADRA2C (0.80) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL28122103 | 0.89 | ADRA2C (0.79) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL7077636 | 0.87 | ADRA2C (0.77) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL328244 | 0.84 | ADRA2C (0.71) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL2627250 | 0.83 | ADRA2C (0.71) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL29833178 | 0.83 | ADRA2C (0.69) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL28845811 | 0.83 | ADRA2C (0.70) | ADRA2CMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL15289763 | 0.81 | ADRA2C (0.68) | ADRA2CMAPTKDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011344-A | Photo-thermal stable PTAA copolymer and preparation method thereof | 链行走新材料科技(广州)有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-114380822-A | CDKs inhibitor of beta-carboline mother nucleus, preparation method and anti-tumor application thereof | 中国人民解放军北部战区总医院 | 2022-04-22 | — | — | CN | claimed |
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| EP-2190834-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | claimed |
| EP-2065380-A1 | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-03 | — | — | EP | claimed |
| WO-2009024332-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | claimed |
| EP-1542982-A1 | HAIR DYES COMPRISING M-PHENYLENEDIAMINE DERIVATIVES AS COUPLING COMPONENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 2005-06-22 | — | — | EP | claimed |
| WO-2004031164-A1 | HAIR DYES COMPRISING M-PHENYLENEDIAMINE DERIVATIVES AS COUPLING COMPONENTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-04-15 | — | — | WO | claimed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| CN-117886824-B | 2, 3-Dihydropyrimido [4,5-d ] pyrimidine-4 (1H) -ketone derivative, preparation method and application thereof | 四川大学华西医院 | 2026-05-15 | — | — | CN | disclosed |
| CN-122011344-A | Photo-thermal stable PTAA copolymer and preparation method thereof | 链行走新材料科技(广州)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | SUTTER BAY HOSPITALS (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| US-5358948-A | Psychological, nervous system disorders | GLAXCO GROUP LIMITED (GB) | 1994-10-25 | — | — | US | disclosed |
| WO-1994003437-A1 | BENZODIAZEPINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993006084-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | ADRA2C 3512/4885MAPT 553/4885KDM4E 1086/4885 |
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | CARM1, MALT1, RCOR1 | ADRA2C 127/4885MAPT 3480/4885KDM4E 3117/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | ADRA2C 1960/4885MAPT 4003/4885KDM4E 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.